Ami Organics Limited Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals is all set to make a debut on the stock market with an issue size of 569.64 Cr.
Ami Organics Limited IPO –Overview
| Ami Organics Limited IPO Issue Date | 1-3 September 2021 |
| Ami Organics Limited IPO Opening Date | 1 September 2021 |
| Ami Organics Limited IPO Face Value | INR 10 per share |
| Ami Organics Limited IPO Price | INR 610 per share |
| Ami Organics Limited IPO Lot Size | 24 Shares |
| Issue Size | 569.64 Cr |
| Offer for sale | 369.64 Cr |
| Issue Type | Book built Issue IPO |
| Listing At | BSE, NSE |
| QIB Shares Offered | 86.64 times |
| NII (HNI) Shares | 154.61 times |
| Company Promoters | Naresh Kumar Ramjibhai Patel, Chetankumar Chhaganlal Vaghasia, Shital Nareshbhai Patel, and Parul Chetankumar Vaghasia are the company promoters |
Ami Organics Limited IPO-Tentative Dates
| Ami Organics Limited IPO opening date | 1 September 2021 |
| Ami Organics Limited IPO closing date | 3 September 2021 |
| Basis of Allotment | 8 September 2021 |
| Initiation of Refunds | 9 September 2021 |
| The credit of Shares to Demat | 13 September 2021 |
| Ami Organics Limited IPO Listing Date | 14 September 2021 |
Industry Overview.
The global chemicals Industry market is valued at around USD 4,738 Bn in 2019 with China accounting for the major market share (40%) in the segment followed by European Union (14%) and the United States (13%). India accounts for ~3.5% market share in the global chemicals market. The global chemicals market is expected to grow at 6.2% CAGR; reaching USD 6,785 Bn by 2025. Going forward the APAC is anticipated to grow at the fastest rate of 7-8% during the forecast period (2019-25F). The chemicals markets in Western Europe, North America, and Japan are relatively mature and hence would record slow growth rates of around 3-4%.
Specialty chemicals are low-volume and high-value products that are sold based on their quality or utility, rather than composition. Thus, they may be used primarily as additives or to provide a specific attribute to the end product. Specialty chemicals are more likely to be prepared and processed in batches. The focus is on value addition to the product and the properties or technical specifications of the chemical.
Company Overview
It is the leading research and development (“R&D”) driven manufacturer of specialty chemicals with varied end usage, focused towards the development and manufacturing of advanced pharmaceutical intermediates (“Pharma Intermediates”) for regulated and generic active pharmaceutical ingredients (“APIs”) and New Chemical Entities (“NCE”) and key starting material for agrochemical and fine chemicals, especially from our recent acquisition of the business of Gujarat Organics Limited (“GOL”)(“Acquisition”). As per the F&S Report, they are one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib, and Rivaroxaban.
The Pharma Intermediates which manufacture, find application in certain high-growth therapeutic areas including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant, commanding significant market share both in India and globally.
It has developed and commercialized over 450Pharma Intermediates for APIs across 17 key therapeutic areas since inception and NCE, with a strong focus on R&D across select high-growth high-margin therapeutic areas such as anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant, for use across the global pharmaceutical market.
IPO-Objectives
- Repayment/prepayment of certain financial facilities availed by our Company.
- Funding working capital requirements of our Company.
- General corporate purposes.
Financial Statements
| Particulars | 31-Mar-21 | 31-Mar-20 | 31-Mar-19 |
| Total Assets | 4,132.68 | 2,318.92 | 2,131.52 |
| Total Revenue | 3,419.88 | 2,424.86 | 2,388.96 |
| Profit After Tax | 539.99 | 274.7 | 232.95 |
IPO Strengths
- One of the leading manufacturers of certain Pharma Intermediates like Dolutegravir, Trazodone, Entacapone, Nintedanib, and Rivaroxaban.
- Strong and diversified product portfolio with 450+ Pharma Intermediates across 17 therapeutic areas.
- Extensive geographical presence and diversified customer base.
- Strong R&D, sales, and marketing capabilities
- Consistent financial performance track record.
Ami Organics Limited IPO Weakness
- Dependency upon its quality controls and standards for the acceptability of its project.
- Captial incentive business.
Company Contact Information
Ami Organics Limited
Plot No. 440/4, 5 & 6, Road No. 82/A
GIDC Sachin, Surat – 394 230
Phone: +91 261 239 7193
Email: cs@amiorganics.com
Website: http://www.amiorganics.com/
Ami Organics IPO Registrar
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: amiorganics.ipo@linkintime.co.in
Website: https://linkintime.co.in/
Ami Organics IPO Lead Manager(s)
- Ambit Private Limited
- Axis Capital Limited
- Intensive Fiscal Services Private Limited
